Decreased lymphoma-related deaths and improved long-term relative survival with radiotherapy for early-stage diffuse large B-cell lymphoma in the rituximab era.

[1]  R. Tsang,et al.  Influence of age on long-term net survival benefit for early-stage MALT lymphomas treated with radiotherapy: A SEER database analysis (2000-2015). , 2022, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[2]  M. Kersten,et al.  Time trends in primary therapy and relative survival of diffuse large B-cell lymphoma by stage: a nationwide, population-based study in the Netherlands, 1989–2018 , 2022, Blood Cancer Journal.

[3]  L. Sehn,et al.  Limited-stage Diffuse Large B-cell Lymphoma. , 2021, Blood.

[4]  R. Advani,et al.  Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. , 2021, Blood.

[5]  J. Tward,et al.  Secondary malignancies in non‐Hodgkin lymphoma survivors: 40 years of follow‐up assessed by treatment modality , 2021, Cancer medicine.

[6]  S. Barta,et al.  2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management , 2021, American journal of hematology.

[7]  L. Sehn,et al.  Diffuse Large B-Cell Lymphoma. , 2021, The New England journal of medicine.

[8]  C. Andrade.  Mean Difference, Standardized Mean Difference (SMD), and Their Use in Meta-Analysis: As Simple as It Gets. , 2020, The Journal of clinical psychiatry.

[9]  V. Seshan,et al.  Clinical Characteristics and Outcomes of Extranodal Stage I Diffuse Large B Cell Lymphoma in The Rituximab-Era. , 2020, Blood.

[10]  Sonali M. Smith,et al.  Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  K. Smedby,et al.  Survival of very elderly patients with diffuse large B‐cell lymphoma according to treatment intensity in the immunochemotherapy era: a Swedish Lymphoma Register study , 2020, British journal of haematology.

[12]  S. Duffy,et al.  Errors in determination of net survival: cause-specific and relative survival settings , 2020, British Journal of Cancer.

[13]  J. Huh,et al.  Distinct clinical characteristics at diagnosis in patients with late relapses compared with early relapses of diffuse large B-cell lymphoma treated with R-CHOP , 2020, Leukemia & lymphoma.

[14]  A. Rosenwald,et al.  Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial , 2019, The Lancet.

[15]  J. Cerhan,et al.  Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Ziepert,et al.  Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  R. Houot,et al.  R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma. , 2018, Blood.

[18]  A. Mariotto,et al.  Cancer‐specific mortality, cure fraction, and noncancer causes of death among diffuse large B‐cell lymphoma patients in the immunochemotherapy era , 2017, Cancer.

[19]  J. Cerhan,et al.  2016 US lymphoid malignancy statistics by World Health Organization subtypes , 2016, CA: a cancer journal for clinicians.

[20]  Sonali M. Smith,et al.  Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  E. B. Butler,et al.  Changes in treatment patterns and impact of radiotherapy for early stage diffuse large B cell lymphoma after Rituximab: A population-based analysis , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[22]  S. Beriwal,et al.  Treatment Selection and Survival Outcomes in Early-Stage Diffuse Large B-Cell Lymphoma: Do We Still Need Consolidative Radiotherapy? , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  L. Gordon,et al.  Radiation for diffuse large B‐cell lymphoma in the rituximab era: Analysis of the National Comprehensive Cancer Network lymphoma outcomes project , 2015, Cancer.

[24]  A. Ng,et al.  Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group. , 2014, International journal of radiation oncology, biology, physics.

[25]  C. Rübe,et al.  Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Cerhan,et al.  Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Lane F Burgette,et al.  A tutorial on propensity score estimation for multiple treatments using generalized boosted models , 2013, Statistics in medicine.

[28]  M Ladetto,et al.  Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  R. Gascoyne,et al.  Limited‐stage diffuse large B‐cell lymphoma treated with abbreviated systemic therapy and consolidation radiotherapy , 2012, Cancer.

[30]  Janez Stare,et al.  On Estimation in Relative Survival , 2012, Biometrics.

[31]  A. López-Guillermo,et al.  CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. , 2011, The Lancet. Oncology.

[32]  P. Hoskin,et al.  Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[33]  D. Weisenburger,et al.  Late relapse in patients with diffuse large B‐cell lymphoma , 2010, British journal of haematology.

[34]  B. Coiffier,et al.  Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. , 2010, Blood.

[35]  Christine F. Wogan,et al.  Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  G. Salles,et al.  Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  T. Blakely,et al.  Measuring cancer survival in populations: relative survival vs cancer-specific survival. , 2010, International journal of epidemiology.

[38]  B. Kavanagh,et al.  Cardiac mortality in patients with stage I and II diffuse large B-cell lymphoma treated with and without radiation: a surveillance, epidemiology, and end-results analysis. , 2010, International journal of radiation oncology, biology, physics.

[39]  P. Austin.  Goodness‐of‐fit diagnostics for the propensity score model when estimating treatment effects using covariate adjustment with the propensity score , 2008, Pharmacoepidemiology and drug safety.

[40]  Randy D Gascoyne,et al.  Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  A. Swerdlow,et al.  Risk of second malignancy after non-Hodgkin's lymphoma: a British Cohort Study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  J. Baars,et al.  Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma. , 2006, Blood.

[43]  J. Raemaekers,et al.  Late non-neoplastic events in patients with aggressive non-Hodgkin's lymphoma in four randomized European Organisation for Research and Treatment of Cancer trials. , 2005, Clinical lymphoma & myeloma.

[44]  R. Henderson,et al.  An individual measure of relative survival , 2005 .

[45]  J. Earle,et al.  Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  R. Fisher,et al.  Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. , 1998, The New England journal of medicine.

[47]  F. Ederer,et al.  The relative survival rate: a statistical methodology. , 1961, National Cancer Institute monograph.

[48]  E. Steliarova-Foucher,et al.  Global patterns and trends in the incidence of non-Hodgkin lymphoma , 2019, Cancer Causes & Control.